Oncology Medical News about chronic myeloid leukemia

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Long-term outcome of patients with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
Blood, 07/02/09

Jabbour E et al. - The correlations with overall survival were not seen for advanced phases. Mutation scoring can predict outcome in CML-CP with imatinib failure treated with second generation TKIs and can help in therapy selection. More complex prognostic models will be required for advanced stages of disease.

<< Previous
Isolation of tumour stem-like cells from benign tumours

Next >>
Characterisation of fibronectin-mediated FAK signalling pathways...